Page 49 - CIBERSAM2016-ENG

• Genetic basis of the different psychiatric disorders mentioned above through multiple approaches that include Genome-Wide Association Studies (GWAS), candidate-gene association studies, analyses of transcriptomic profiles with microarray technology and next-generation sequencing as well as animal model approaches. Unraveling the genetic basis of these conditions may help to improve diagnostic procedures, provide clues about predictive risk factors and allow the identification of new targets that may eventually lead to novel and more individualized pharmacological treatments.
Most relevant scientific articles
• Ramos-Quiroga JA, Nasillo V, Richarte V, Corrales M, Palma F, Ibáñez P et al. Criteria and Concurrent Validity of DIVA 2.0: A Semi-Structured Diagnostic Interview for Adult ADHD.Journal of attention disorders. 2016.
• Ferrer M, Andión Ó, Calvo N, Ramos-Quiroga JA, Prat M, Corrales M et al. Differences in the association between childhood trauma history and borderline personality disorder or attention deficit/hyperactivity disorder diagnoses in adulthood.European archives of psychiatry and clinical neuroscience. 2016.
• Pagerols M, Richarte V, Sánchez-Mora C, Garcia-Martínez I, Corrales M, Corominas M et al. Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder. The pharmacogenomics journal. 2016.
• Stringer S, Minică CC, Verweij KJ, Mbarek H, Bernard M, Derringer J et al. Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium.Translational psychiatry. 2016;6: e769.
• Garcia-Martínez I, Sánchez-Mora C, Pagerols M, Richarte V, Corrales M, Fadeuilhe C et al. Preliminary evidence for association of genetic variants in pri-miR-34b/c and abnormal miR-34c expression with attention deficit and hyperactivity disorder.Translational psychiatry. 2016;6(8): e879.
Hightlights
In 2016 the research group has led multiples competitive research projects including five European projects (Agressotype, MiND, CoCA, Eat2bNice and MyHealth),
The Group has focused its research on the etiological, clinical and therapeutic aspects of disorders characterized by a high impulsivity that affects the individual across lifespan, focusing its Interest in Attention Deficit Hyperactivity Disorder (ADHD), Personality Limit Disorder (BPD) and Substance Use Disorders (SUD).
The main lines of research include:
• Genome-wide (GWAS) and candidate gene association studies to identify the genetic basis of the previously
mentioned psychiatric disorders.
• To evaluate the impact of polygenic risk for ADHD on neurocognitive functions, learning disorders, academic
performance or comorbid disorders such as Substance Use Disorders.
• To explore protein-coding and non-coding RNA expression profiling in medicated-naive ADHD subjects and
healthy controls using next-generation sequencing and microarray technology.
• To explore differential epigenome signatures associated with ADHD through DNA-methylation
• Pharmacogenetics of methylphenidate response and tolerability in ADHD.
• Characterization of the intestinal microbiota in patients with ADHD through metagenomic-wide association
study (MGWAS) through next generation sequencing of DNA from faecal samples.
• To study how the different neurodevelopmental disorders affect the functionality of patients, including the
study of academic performance, traffic accidents and criminal behaviour.
• Validation of new psychometric instruments on ADHD and BPD.
• Application of eHealth programs for the assessment and treatment of mental disorders, as virtual reality.
• Performing neuroimaging studies in disorders such as fetal alcohol syndrome, ADHD and BPD.
• To determine the prevalence of psychopathology in the immigrant population, as well as to develop specific
assessment instruments for psychopathology in the immigrant population.
SAM
research groups 49